Apoptosis - associated genes and their role in predicting responses to neoadjuvant breast cancer treatment

Medical Science Monitor

Volumn 18, Issue 1, 2012, Pages

  Tvrdík, Daniel ^a   Skálová, Helena ^a   Dundr, Pavel ^a   Povýšil, Ctibor ^a   Velenská, Zuzana ^a   Berková, Adéla ^a   Staněk, Libor ^a   Petruželka, Luboš ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Apoptosis; Biomarkers; Breast cancer; Neoadjuvant chemotherapy

Indexed keywords

BIOLOGICAL MARKER; CASPASE 10; CASPASE 14; CASPASE 3; CASPASE 8; CD30 LIGAND; CD70 ANTIGEN; CYCLOPHOSPHAMIDE; DEATH RECEPTOR 3; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FLUOROURACIL; LETROZOLE; MOLECULAR MARKER; PACLITAXEL; PROTEIN BCL 2; PROTEIN MCL 1; SOMATOMEDIN C RECEPTOR; TAMOXIFEN; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLUSTER ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; ENZYME ASSAY; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MULTIPLE CYCLE TREATMENT; NEEDLE BIOPSY; NICK END LABELING; PROGNOSIS; PROGRESSION FREE SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; TUMOR REGRESSION; UPREGULATION;

EID: 84855296004     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.882205     Document Type: Article

References (37)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics. CA Cancer J Clin, 2005; 55: 74-108
2. Buchholz TA, Hunt KK, Whitman GJ et al: Neoadjuvant chemotherapy for Brest carcinoma. Cancer, 2003; 98: 1150-60
3. Jones C, Ford E, Gillett C et al: Molecular cytogenetic identification of subgroups of grade III invasive ductal breast carcinomas with different clinical outcomes. Clin Cancer Res, 2004; 10: 5988-97
4. Goldhirsch A, Glick JH, Gelber RD et al: Meeting Highlights: Intemationa1 Expert Consensus on the Primary Therapy of Early Breast Cancer 2005. Ann Oncol, 2005; 16: 1569-83
5. Eifel P, Axelson JA, Costa J et al: NIH Consensus Development Panel: Adjuvant Therapy for Breast Cancer. J Natl Cancer Inst, 2001; 93: 979-89
6. Oakman C, Santarpia L, Di Leo A: Breast cancer assessment tools and optimizing adjuvant therapy. Nat Rev Clin Oncol, 2010; 7: 725-32
7. Reis-Filho JS, Westbury C, Pierga JY: The impact of expression profiling on prognostic and predictive testing in breast cancer. J Clin Pathol, 2006; 59: 225-31
8. Sotiriou C, Powles TJ, Dowsett M et al: Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res, 2002; 4: R3
9. Pluciennik E, Krol M, Nowakowska M et al: Breast cancer relapse prediction based on multi-gene RT-PCR algorithm. Med Sci Monit, 2010; 16(3): 132-36
10. Perou CM, Sorlie T, Eisen MB et al: Molecular portraits of human breast tumours. Nature, 2000; 406: 747-52
11. Sorlie T, Perou CM, Tibshirani R et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA, 2001; 98: 10869-74
12. Sotiriou C, Neo SY, McShane LM et al: Breast cancer c1assification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA, 2003; 100: 10393-98
13. van't Veer LJ, Dai H, van de Vijver MJ et al: Gene expression profi1ing predicts c1inical outcome of breast cancer. Nature, 2002; 415: 530-36
14. Goldhirsch A, Ingle JN, Gelber RD et al: Thresholds for therapies: high-lights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009, Ann Oncol, 2009; 20: 1319-29
15. Tavassoli FA, Devilee P: WHO Classification of tumours. Pathology and genetics tumours of the breast and female genital organs. Lyon: IARC Press, 2004
16. Normanno N, De Luca A, Carotenuto P et al: Prognostic Applications of Gene Expression Signatures in Breast Cancer. Oncology, 2009; 77(Suppl.1): 2-8
17. Skálová H, Dundr P, Povýšil C et al: Altered expression of Her2/neu after neoadjuvant treatment of breast cancer. Folia Biologica, 2011; 57(5): 191-99
18. Tvrdík, D, Svatošová J, Dundr P, Povýšil C: Molecular diagnosis of synovial sarcoma: detection of SYT-SSX1/2 fusion transcripts by RT-PCR in paraffin-embedded tissue. Med Sci Monit, 2005; 11(3): 1-7
19. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods, 2001; 25: 402-8
20. Li Z, Liu B, Maminishkis A et al: Gene expression profiling in autoimmune noninfectious uveitis disease. J Immunol, 2008; 181: 5147-57
21. Duan WR, Garner DS, Williams SD et al: Comparison of immunohis-tochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcutaneous xenografts. J Pathol, 2003; 199: 221-28
22. Bauer K, Parise C, Caggiano V: Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer. BMC Cancer, 2010; 10: 228-40
23. Van de Vijver M: Gene-Expression Profiling and the Future of Adjuvant Therapy. The Oncologist, 2005; 10(Suppl.2): 30-34
24. Chang JC, Wooten EC, Tsimelzon A et al: Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet, 2003; 362: 362-69
25. Kerr JF, Winterford CM, Harmon BV: Apoptosis. Its significance in cancer and cancer therapy. Cancer, 1994; 73: 2013-26
26. Leist M and Jäättelä M: Four deaths and a funeral: From caspases to alternative mechanisms. Nat Rev Mol Cell Biol, 2001; 2: 589-98
27. Sperandio S, de Belle I, Bredesen DE: An alternative, non-apoptotic form of programmed cell death. Proc Natl Acad Sci USA, 2000; 97: 14376-81
28. Wajant H, Gerspach J, Pfizenmaier K: Engineering death receptor ligands for cancer therapy. Cancer Lett, 2011
29. Daniel PT, Wieder T, Sturm I, Schulze-Osthoff K: The kiss of death: promises and failures of death receptors and ligands in cancer therapy. Leukemia, 2001; 15: 1022-32
30. Inohara N, Ding L, Chen S, Núńez G: Harakiri, a novel regulator of cell death, encodes a protein that activates apoptosis and interacts selectively with survival-promoting proteins Bcl-2 and Bcl-X(L). EMBO J, 1997; 16: 1686-94
31. Rocha RL, Hilsenbeck SG, Jackson JG et al: Insulin-like growth factor binding protein 3 and insulin receptor substrate 1 in breast cancer: correlation with clinical parameters and disease-free survival. Clinical Cancer Research, 1997; 3: 103-9
32. Turner BC, Haffty BG, Narayanan L et al: IGF-I receptor and cyclin D1 expression influence cellular radiosensitivity and local breast cancer recurrence after lumpectomy and radiation. Cancer Research, 1997; 57: 3079-83
33. Inohara N, Koseki T, Chen S et al: CIDE, a novel family of cell death activators with homology to the 45 kDa subunit of the DNA fragmentation factor. EMBO J, 1998; 17: 2526-33
34. Enari M, Sakahira H, Yokoyama H et al: A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature, 1998; 391: 43-50
35. Liu X, Zou H, Slaughter C, Wang X: DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell, 1997; 89: 175-84
36. Liu X, Li P, Widlak P et al: The 40-kDa subunit of DNA fragmentation factor induces DNA fragmentation and chromatin condensation during apoptosis. Proc Natl Acad Sci USA, 1998; 95: 8461-66
37. Sakahira H, Enari M, Nagata S: Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature, 1998; 391: 96-99